Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The Follicular Lymphoma International Prognostic Index (FLIPI) and FLIPI2 are well-known prognostic models for patients with follicular lymphoma (FL). However, their prognostic relevance has not been examined before in Korean patients with FL. Methods: We reviewed clinical and laboratory information from our database of patients between 1995 and 2012. In total, 125 patients were stratified in three categories according to FLIPI or FLIPI2 scores: low-, intermediate-, and high-risk groups. We compared FLIPI and FLIPI2 in terms of progression-free survival (PFS) and overall survival (OS). Results: Among the 125 patients, the prognostic value of FLIPI and FLIPI2 was evaluated in 73 patients who fulfilled the criteria of both prognostic models. Risk stratification by FLIPI and FLIPI2 showed significant differences in unfavorable parameters among each risk group, particularly between low- and intermediate- risk groups. The high-risk group b was significantly associated with poor PFS on both FLIPI and FLIPI2 (p < 0.05). However, the OS was significantly different only in the risk groups determined by FLIPI2 (p = 0.042). In a subgroup analysis of patients who received rituximab-containing chemotherapy, the risk stratification of both prognostic models showed a significant impact on PFS, especially in the low-risk group. Conclusions: FLIPI and FLIPI2 are appropriate prognostic models in Korean FL patients, especially for discriminating low-risk patients from intermediate- and high-risk groups.
Abstract
Background/Aims: The Follicular Lymphoma International Prognostic Index (FLIPI) and FLIPI2 are well-known prognostic models for patients with follicular lymphoma (FL). However, their prognostic relevance has not been examined before in Korean patients with FL. Methods: We reviewed clinical and laboratory information from our database of patients between 1995 and 2012. In total, 125 patients were stratified in three categories according to FLIPI or FLIPI2 scores: low-, intermediate-, and high-risk groups. We compared FLIPI and FLIPI2 in terms of progression-free survival (PFS) and overall survival (OS). Results: Among the 125 patients, the prognostic value of FLIPI and FLIPI2 was evaluated in 73 patients who fulfilled the criteria of both prognostic models. Risk stratification by FLIPI and FLIPI2 showed significant differences in unfavorable parameters among each risk group, particularly between low- and intermediate- risk groups. The high-risk group b was significantly associated with poor PFS on both FLIPI and FLIPI2 (p < 0.05). However, the OS was significantly different only in the risk groups determined by FLIPI2 (p = 0.042). In a subgroup analysis of patients who received rituximab-containing chemotherapy, the risk stratification of both prognostic models showed a significant impact on PFS, especially in the low-risk group. Conclusions: FLIPI and FLIPI2 are appropriate prognostic models in Korean FL patients, especially for discriminating low-risk patients from intermediate- and high-risk groups.
참고문헌 (17)
- Morton LM, "Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001", Blood, 107, pp.265~276 (2006)
- 허주령, "Epidemiologic overview of malignant lymphoma", Blood Research, 47(2), pp.92~104 (2012), 대한혈액학회[DOI]
- Hyeon Jin Park, "Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008", Blood Research, 47(1), pp.28~38 (2012), 대한혈액학회
- Tan D, "Follicular lymphoma: clinical features and treatment", Hematol Oncol Clin North Am, 22, pp.863~882 (2008)
- "The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma", N Engl J Med, 329, pp.987~994 (1993)
- Solal-Celigny P, "Follicular lymphoma international prognostic index", Blood, 104, pp.1258~1265 (2004)
- Federico M, "Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project", J Clin Oncol, 27, pp.4555~4562 (2009)
- Arcaini L, "Validation of follicular lymphoma international prognostic index 2(FLIPI2) score in an independent series of follicular lymphoma patients", Br J Haematol, 149, pp.455~457 (2010)
- Swerdlow SH CE, "World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues" (2008), IARC Press
- "The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma", Blood, 89, pp.3909~3918 (1997)
- Canioni D, "Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d’Etude des Lymphomes Folliculaires", Br J Haematol, 126, pp.364~371 (2004)
- Pettengell R, "Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?", Drugs, 69, pp.1727~1737 (2009)
- Formica V, "Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting firstline treatment efficacy in follicular lymphoma patients", Acta Haematol, 122, pp.193~199 (2009)
- Luminari S, "Prognostic tools in follicular lymphomas", Expert Rev Hematol, 2, pp.549~562 (2009)
- Solal-Celigny P, "Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?", Int J Hematol, 92, pp.246~254 (2010)
- Van de Schans SA, "Validation, revision and extension of the Follicular LymphomaInternational Prognostic Index (FLIPI) in a population-based setting", Ann Oncol, 20, pp.1697~1702 (2009)
- Numata A, "Retrospective study of the utility of FLIPI", FLIPI-2 for follicular lymphoma patients treated with R-CHOP, 2012, pp.52, 77~79